Physician profile
Robert E Golder
NPI 1669461513
$5,180.68
in general payments reported to CMS, 2019-2025
30 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $202 · 2021: $490 · 2022: $1,099 · 2023: $828 · 2024: $755 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,754 · Education: $41.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,753.91 |
| Education | $41.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $879.45 | 2019-2025 | Filspari |
| Calliditas Therapeutics US INC. | $399.03 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $355.06 | 2019-2023 | Korsuva, Veltassa |
| Astrazeneca Pharmaceuticals Lp | $318.96 | 2021-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $316.40 | 2019-2024 | Vafseo, Auryxia |
| Amgen INC. | $302.57 | 2019-2025 | Tavneos, Krystexxa |
| Ani Pharmaceuticals, INC. | $280.74 | 2022-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $255.14 | 2020-2024 | Acthar |
| Otsuka America Pharmaceutical, INC. | $223.76 | 2019-2025 | Jynarque |
| Bayer Healthcare Pharmaceuticals INC. | $200.80 | 2022-2025 | |
| Horizon Therapeutics Plc | $184.18 | 2019-2022 | |
| Medtronic, INC. | $183.92 | 2021-2023 | Chameleon |
| Novartis Pharmaceuticals Corporation | $183.66 | 2024-2025 | |
| Fresenius USA Marketing, INC. | $164.00 | 2019-2025 | Velphoro, Velphoro |
| Opko Pharmaceuticals, LLC | $139.47 | 2019-2023 | Rayaldee |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nxstage Medical, INC. | $132.46 | 2022-2025 | Liberty Select Cycler, Nxstage System One |
| Novo Nordisk INC | $130.24 | 2023-2025 | Ozempic, Rybelsus, Rivfloza |
| Glaxosmithkline, LLC. | $96.41 | 2020-2025 | Benlysta |
| Mozarc Medical US LLC | $83.16 | 2023-2025 | Chameleon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.47 | 2023-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $68.80 | 2019 | |
| Shield Therapeutics INC | $35.32 | 2025 | |
| Aurinia Pharma U.S., INC. | $33.97 | 2022-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $32.85 | 2022-2024 | Ultomiris |
| Scpharmaceuticals INC. | $21.32 | 2025 | |
| Pharmacosmos Therapeutics INC. | $19.76 | 2024 | Monoferric |
| Janssen Pharmaceuticals, INC | $17.63 | 2019 | |
| Ardelyx, INC. | $16.60 | 2025 | Ibsrela |
| Apellis Pharmaceuticals, INC. | $15.67 | 2025 | Empaveli |
| Sanofi-Aventis U.S. LLC | $13.88 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Golder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.